Department of Hematology and Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center for Cancer, Tianjin, P.R. China
Department of Hematology and Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center for Cancer, Tianjin, P.R. China.
Biosci Rep. 2019 Aug 13;39(8). doi: 10.1042/BSR20191162. Print 2019 Aug 30.
In the present study, we aim to examine the relationship between genetic polymorphism and transcriptional expression of cyclic AMP response element binding protein () and the risk of diffuse large B-cell lymphoma (DLBCL). Two hundred and fifty healthy individuals and 248 DLBCL patients participated in the present study. The rs3025684 polymorphism was detected by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The mRNA expression of was tested by the real-time quantitative PCR (RT-qPCR). The allele A frequency of rs3025684 in DLBCL patients was obviously higher than that of controls (=0.01). No significant difference was detected between rs3025684 polymorphism and clinical characteristics of DLBCL patients when subgrouped according to different parameters. The results demonstrated that the allele A of rs3025684 increased the susceptibility to DLBCL (=0.004), with a worse overall survival (OS) rate (=0.002), a worse progression-free survival (PFS) rate (=0.033) and poor prognosis (=0.003) in DLCBL patients. Furthermore, the expression of mRNA was considerably decreased in DLBCL patients as compared with controls (<0.001), and the expression in patients with GG genotype was up-regulated in comparison with patients with GA and AA genotype (=0.016 and =0.001, respectively). However, no statistical differences were found in OS (=0.201) and PFS (=0.353) between the lower mRNA level subgroup and higher mRNA level subgroup. These data suggested that the gene may be an important prognostic factor in DLBCL patients and perform an essential function in the development of DLBCL.
在本研究中，我们旨在研究环磷酸腺苷反应元件结合蛋白 () 的遗传多态性与转录表达与弥漫性大 B 细胞淋巴瘤（DLBCL）风险之间的关系。250 名健康个体和 248 名 DLBCL 患者参与了本研究。通过聚合酶链反应-限制性片段长度多态性（PCR-RFLP）检测 rs3025684 多态性。通过实时定量 PCR（RT-qPCR）检测 的 mRNA 表达。在 DLBCL 患者中，rs3025684 的等位基因 A 频率明显高于对照组（=0.01）。当根据不同参数对 DLBCL 患者进行亚组分析时，rs3025684 多态性与 DLBCL 患者的临床特征之间未检测到显著差异。结果表明，rs3025684 的等位基因 A 增加了 DLBCL 的易感性（=0.004），DLBCL 患者的总生存率（OS）率（=0.002）、无进展生存率（PFS）率（=0.033）和预后不良（=0.003）。此外，与对照组相比，DLBCL 患者的 mRNA 表达明显降低（<0.001），并且 GG 基因型患者的表达与 GA 和 AA 基因型患者相比上调（=0.016 和 =0.001）。然而，在 OS（=0.201）和 PFS（=0.353）方面，低 mRNA 水平亚组与高 mRNA 水平亚组之间未发现统计学差异。这些数据表明，基因可能是 DLBCL 患者的一个重要预后因素，并在 DLBCL 的发展中发挥重要作用。
